Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines

被引：156

作者：

Barrett, P. Noel ^{[1
]}

Mundt, Wolfgang ^{[2
]}

Kistner, Otfried ^{[1
]}

Howard, M. Keith ^{[1
]}

机构：

[1] Baxter BioSci, Biomed Res Ctr, A-2304 Orth, Austria

[2] IZD Tower, Baxter BioSci, A-1220 Vienna, Austria

来源：

EXPERT REVIEW OF VACCINES | 2009年 / 8卷 / 05期

关键词：

continuous cell line; emerging virus disease; influenza; rotavirus; smallpox; Vero; viral vaccine; JAPANESE ENCEPHALITIS VACCINE; NILE-VIRUS ISOLATION; ATTENUATED VACCINE; INFLUENZA-VIRUS; PROTECTIVE EFFICACY; CLINICAL-TRIALS; EGG-ADAPTATION; CHIMERIVAX-JE; DENGUE; LIVE;

D O I：

10.1586/ERV.09.19

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authorities as improved screening technologies remove fears regarding their potential oncogenic properties. The Vero cell line is the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines. The recent licensure of a Vero cell-derived live virus vaccine (ACAM2000, smallpox vaccine) has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza. These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases.

引用

页码：607 / 618

页数：12

共 91 条

[1] AN EPIDEMIC OF ROSS RIVER VIRUS-INFECTION IN FIJI, 1979 [J].

AASKOV, JG ;

MATAIKA, JU ;

LAWRENCE, GW ;

RABUKAWAQA, V ;

TUCKER, MM ;

MILES, JAR ;

DALGLISH, DA .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1981, 30 (05) :1053-1059

[2]

[Anonymous], 2006, GUID IND CHAR QUAL C

[3]

[Anonymous], VACCINES

[4] ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy [J].

Arroyo, J ;

Miller, C ;

Catalan, J ;

Myers, GA ;

Ratterree, MS ;

Trent, DW ;

Monath, TP .

JOURNAL OF VIROLOGY, 2004, 78 (22) :12497-12507

[5]

Bernstein David I, 2006, Semin Pediatr Infect Dis, V17, P188, DOI 10.1053/j.spid.2006.08.006

[6] Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1 [J].

Blaney, Joseph E., Jr. ;

Sathe, Neeraj S. ;

Hanson, Christopher T. ;

Firestone, Cai Yen ;

Murphy, Brian R. ;

Whitehead, Stephen S. .

VIROLOGY JOURNAL, 2007, 4 (1)

[7] Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4 [J].

Blaney, Joseph E., Jr. ;

Sathe, Neeraj S. ;

Goddard, Laura ;

Hanson, Christopher T. ;

Romero, Tammy A. ;

Hanley, Kathryn A. ;

Murphy, Brian R. ;

Whitehead, Stephen S. .

VACCINE, 2008, 26 (06) :817-828

[8] West Nile virus [J].

Campbell, GL ;

Marfin, AA ;

Lanciotti, RS ;

Gubler, DJ .

LANCET INFECTIOUS DISEASES, 2002, 2 (09) :519-529

[9] The new pentavalent rotavirus vaccine composed of bovine (Strain WC3)-human rotavirus reassortants [J].

Clark, H. Fred ;

Offit, Paul A. ;

Plotkin, Stanley A. ;

Heaton, Penny M. .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (07) :577-583

[10] Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association [J].

Dang-Tan, T ;

Mahmud, SM ;

Puntoni, R ;

Franco, EL .

ONCOGENE, 2004, 23 (38) :6535-6540

← 1 2 3 4 5 6 7 8 9 10 →